Pharmacokinetics of troglitazone, an antidiabetic agent: Prediction of in vivo stereoselective sulfation and glucuronidation from in vitro data

Journal of Pharmacology and Experimental Therapeutics

Volumn 280, Issue 3, 1997, Pages 1392-1400

  Izumi, Takashi ^a   Hosiyama, Kazuko ^a   Enomoto, Sachiko ^a   Sasahara, Kunihiro ^a   Sugiyama, Yuichi ^b  

^a DAIICHI SANKYO CO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCURONOSYLTRANSFERASE; ORAL ANTIDIABETIC AGENT; SULFOTRANSFERASE; TROGLITAZONE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG GLUCURONIDATION; DRUG SULFATION; DRUG URINE LEVEL; ENZYME KINETICS; LIVER CYTOSOL; LIVER MICROSOME; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; STEREOISOMERISM;

ANIMALS; BILE; CHROMANS; CYTOSOL; GLUCURONATES; HYPOGLYCEMIC AGENTS; LIVER; MALE; MICE; MICE, INBRED STRAINS; MICROSOMES, LIVER; RATS; RATS, WISTAR; SPECIES SPECIFICITY; STEREOISOMERISM; SULFATES; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0030973810     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. BURCHELL, B. AND COUGHTRIE, M. W.: UDP-glucuronosyltransferases. Pharmacol. Ther. 43: 261-289, 1989.
2. COUGHTRIE, M. W., ASK, B., RANE, A., BURCHELL, B. AND HUME, R.: The enantioselective glucuronidation of morphine in rats and humans: Evidence for the involvement of more than one UDP-glucuronosyltransferase isoenzyme. Biochem. Pharmacol. 38: 3273-3280, 1989.
3. DAVIES, B. AND MORRIS, T.: Physiological parameters in laboratory animals and humans. Pharm. Res. 10: 1093-1095, 1993.
4. EL-MOUELHI, M. AND BOCK, K. W.: Stereoselective (S)- and (R)-naproxen glucuronosyltransferases of rat liver. Drug Metab. Dispos. 19: 304-308, 1991.
5. FUJIWARA, T., YOSHIOKA, S., YOSHIOKA, T., USHIYAMA, I. AND HORIKOSHI, H.: Characterization of new antidiabetic agent CS-045: Studies in KK and ob/ob mice and Zucker fatty rats. Diabetes 37: 1549-1558, 1988.
6. HANSEN, K. T., THOMSEN, K. F. AND BUNDGAARD, H.: Glucuronidation of the dopamine D-1 receptor antagonists NNC 0756 and NNC 0772 in liver microsomes. Drug Metab. Dispos. 20: 172-178, 1992.
7. HOUSTON, J. B.: Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem. Pharmacol. 47: 1469-1479, 1994.
8. IWATSUBO, T., HIROTA, N., OOIE, T., SUZUKI, H. AND SUGIYAMA, Y.: Prediction of in vivo drug disposition from in vitro data based on physiological pharmacokinetics. Biopharm. Drug Dispos. 17: 273-310, 1996.
9. IZUMI, T., ENOMOTO, S., HOSHIYAMA, K., SASAHARA, K., SHIBUKAWA, A., NAKAGAWA, T. AND SUCIYAMA, Y.: Prediction on the human pharmacokinetics of troglitazone, a new and extensively metabolized antidiabetic agent, after oral administration, with an animal scale-up approach. J. Pharmcol. Exp. Ther. 277: 1630-1041, 1996.
10. IZUMI, T., ENOMOTO, S., HOSHIYAMA, K., SASAHARA, K. AND SUGIYAMA, Y.: Stereo-selectivity of troglitazone pharmacokinetics, an antidiabetic agent, in the KK mouse. Biopharm. Drug Dispos., in press, 1997.
11. KAWAI, K., KAWASAKI-TOKUI, Y., ODAKA, T., TSUEUTA, F., KAZUI, M., IWABUCHI, H., KINOSHITA, T., IKEDA, T., KOMAI, T. AND NAKAMURA, K.: Disposition and metabolism of troglitazone (CS-045), a new antidiabetic drug, in rats, mice and dogs. Arzneim.-Forsch. Drug Res., in press, 1997.
12. KUTT, H. AND FOUTS, J. R.: Diphenylhydantoin metabolism by rat liver microsomes and some of the effects of drug or chemical pretreatment on diphenylhydantoin metabolism by rat liver microsomal preparations. J. Pharmcol. Exp. Ther. 176: 11-26, 1971.
13. LETT, E., KRISZT, W., DE SANDRO, V., DUCROTOY, G. AND RICHERT, L.: Optimal detergent activation of rat liver microsomal UDP-glucuronosyl transferases toward morphine and 1-naphthol: Contribution to induction and latency studies. Biochem. Pharmacol. 43: 1649-1653, 1992.
14. LIN, J. H., SUGIYAMA, Y., AWAZU, S. AND HANANO, M.: Kinetic studies on the deethylation of ethoxybenzamide: A comparative study with isolated hepatocytes and liver microsomes of rat. Biochem. Pharmcol. 29: 2825-2830, 1980.
15. MATSUBARA, T., KOIKE, M., TOCHINO, A., TOCHINO, Y. AND SUGENO, K.: Quantitative determination of cytochrome P-450 in rat liver homogenates. Anal. Biochem. 75: 596-603, 1976.
16. MISTRY, M. AND HOUSTON, J. B.: Glucuronidation in vitro and in vivo: Comparison of intestinal and hepatic conjugation of morphine, naloxone, and buprenorphine. Drug Metab. Dispos. 15: 710-717, 1987.
17. MORRIS, M. E. AND PANG, K. S.: Competition between two enzymes for substrate removal in liver: Modulating effects due to substrate recruitment of hepatocyte activity. J. Pharmacokinet. Biopharm. 15: 473-496, 1987.
18. OBACH, R. S.: The importance of nonspecific binding in in vitro matrices, its impact on enzyme kinetic studies of drug metabolism reactions, and implications for in vitro-in vivo correlations. Drug Metab. Dispos. 24: 1047-1049, 1996.
19. OMURA, T. AND SATO, R.: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239: 2370-2378, 1964.
20. PACIFICI, G. M., BACK, D. J. AND ORME, M. L.: Sulphation and glucuronidation of paracetamol in human liver: Assay conditions. Biochem. Pharmacol. 22: 4405-4407, 1988.
21. PANG, K. S., Xu, X. AND ST. PIERRE, M. V.: Determination of metabolite disposition. Annu. Rev. Pharmacol. Toxicol. 32: 623-669, 1992.
22. PESOLA, G. R. AND WALLE, T.: Stereoselective sulfate conjugation of isoproterenol in humans: Comparison of hepatic, intestinal, and platelet activity. Chirality 5: 602-609, 1993.
23. RANE, A., SAWE, J., LINDBERG, B., SVENSSON, J. O., GARLE, M., ERWALD, R. AND JORULF, H.: Morphine glucuronidation in the rhesus monkey: A comparative in vivo and in vitro study. J. Pharmacol. Exp. Ther. 229: 571-576, 1984.
24. RANE, A., WILKINSON, G. R. AND SHAND, D. G.: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmcol. Exp. Ther. 200: 420-424, 1977.
25. ROBERTS, M. S. AND ROWLAND, M.: Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: Analysis with a dispersion model. J. Pharm. Pharmacol. 38: 177-181, 1986a.
26. ROBERTS, M. S. AND ROWLAND, M.: A dispersion model of hepatic elimination. 3. Application to metabolite formation and elimination kinetics. J. Pharmacokinet. Biopharm. 14: 289-308, 1986b.
27. SEKURA, R. D. AND JAKOBY, W. B.: Phenol sulfotransferases. J. Biol. Chem. 254: 5658-5663, 1979.
28. SHIBUKAWA, A., SAWADA, T., NAKAO, C., IZUMI, T. AND NAKAGAWA, T.: Highperformance frontal analysis for the study of protein binding of troglitazone (CS-045) in albumin solution and human plasma. J. Chromatogr. A, 697: 337-347, 1995.
29. SUGIYAMA, Y., SAWADA, Y., IGA, T. AND HANANO, M.: Reconstruction of in vivo metabolism from in vitro data. In Xenobiotic Metabolism and Disposition: Proceedings of the Second International Meeting of International Society for the Study of Xenobiotics, ed. by R. Kato, R. W. Estabrook and M. N. Cayen, pp. 225-235, Taylor & Francis, London, 1989.
30. SUTER, S. L., NOLAN, J. J., WALLACE, P., GUMBINER, B. AND OLEFSKY, J. M.: Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15: 193-203, 1992.
31. WALLE, U. K., PESOLA, G. R. AND WALLE, T.: Stereoselective sulphate conjugation of salbutamol in humans: Comparison of hepatic, intestinal and platelet activity. Br. J. Clin. Pharmacol. 35: 413-418, 1993.
32. WILKINSON, G. R.: Clearance approaches in pharmacology. Pharmacol. Rev. 39: 1-47, 1987.
33. YAMAOKA, K., NAKAGAWA, T. AND UNO, T.: Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6: 165-175, 1978.
34. YAMAOKA, K., TANIGAWARA, Y., NAKAGAWA, T. AND UNO, T.: A pharmacokinetic analysis program (MULTI) for microcomputer. J. Pharmacobio-Dyn. 4: 879-885, 1981.
35. YOSHIOKA, T., AIZAWA, Y., FUJITA, T., NAKAMURA, K., SASAHARA, K., KUWANO, H., KINOSHITA, T. AND HORIKOSHI, H.: Studies on hindered phenols and analogues. V. Synthesis, identification, and antidiabetic activity of the glucuronide of CS-045. Chem. Pharm. Bull. (Tokyo) 39: 2124-2125, 1991.
36. YOSHIOKA, T., FUJITA, T., KANAI, T., AIZAWA, Y., KURUMADA, T. AND HASEGAWA, K.: Studies on hindered phenols and analogues. 1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation. J. Med. Chem. 32: 421-428, 1989.
37. YOSHIOKA, T., HORIKOSHI, H., NAKAMURA, K., SASAHARA, K. AND TAKEBAYASHI, K.: 5-[4-(2-Chromanylalkoxy)benzyl]-2,4-thiazolidineones for treatment of diabetes. Chem. Abstr. 107: 176024C, 1987.